104 related articles for article (PubMed ID: 21036718)
1. Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.
Liu IH; Chang CH; Ho CL; Chiu SP; Lee WC; Chang TJ; Chen LC; Wu YH; Chuang CH; Fu YK; Lee TW
Anticancer Res; 2010 Oct; 30(10):4039-48. PubMed ID: 21036718
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumor-bearing mice.
Ho CL; Liu IH; Wu YH; Chen LC; Chen CL; Lee WC; Chuang CH; Lee TW; Lin WJ; Shen LH; Chang CH
J Biomed Biotechnol; 2011; 2011():101497. PubMed ID: 21660132
[TBL] [Abstract][Full Text] [Related]
3. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
4. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
[TBL] [Abstract][Full Text] [Related]
5. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites.
Linder KE; Metcalfe E; Arunachalam T; Chen J; Eaton SM; Feng W; Fan H; Raju N; Cagnolini A; Lantry LE; Nunn AD; Swenson RE
Bioconjug Chem; 2009 Jun; 20(6):1171-8. PubMed ID: 19480415
[TBL] [Abstract][Full Text] [Related]
7. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
[TBL] [Abstract][Full Text] [Related]
8. Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA.
Cagnolini A; Chen J; Ramos K; Skedzielewski TM; Lantry LE; Nunn AD; Swenson RE; Linder KE
Appl Radiat Isot; 2010 Dec; 68(12):2285-92. PubMed ID: 20638858
[TBL] [Abstract][Full Text] [Related]
9. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
11. In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.
Thomas R; Chen J; Roudier MM; Vessella RL; Lantry LE; Nunn AD
Clin Exp Metastasis; 2009; 26(2):105-19. PubMed ID: 18975117
[TBL] [Abstract][Full Text] [Related]
12. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
13. Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer.
Schroeder RP; De Blois E; De Ridder CM; Van Weerden WM; Breeman WA; de Jong M
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):468-75. PubMed ID: 23069925
[TBL] [Abstract][Full Text] [Related]
14. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.
Schroeder RP; Müller C; Reneman S; Melis ML; Breeman WA; de Blois E; Bangma CH; Krenning EP; van Weerden WM; de Jong M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1386-96. PubMed ID: 20182713
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K
Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides.
Mansi R; Wang X; Forrer F; Kneifel S; Tamma ML; Waser B; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2009 Aug; 15(16):5240-9. PubMed ID: 19671861
[TBL] [Abstract][Full Text] [Related]
17. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors.
Chen J; Linder KE; Cagnolini A; Metcalfe E; Raju N; Tweedle MF; Swenson RE
Appl Radiat Isot; 2008 Apr; 66(4):497-505. PubMed ID: 18178448
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
[TBL] [Abstract][Full Text] [Related]
20. Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA.
Bandari RP; Carmack TL; Malhotra A; Watkinson L; Fergason Cantrell EA; Lewis MR; Smith CJ
J Med Chem; 2021 Feb; 64(4):2151-2166. PubMed ID: 33534560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]